MedPath

Dacarbazine

Dacarbazine for Injection, USP

Approved
Approval ID

b6b97e41-5f15-498c-abfb-d8443ea4d216

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 20, 2022

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DACARBAZINE

PRODUCT DETAILS

NDC Product Code63323-128
Application NumberANDA075371
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateOctober 20, 2022
Generic NameDACARBAZINE

INGREDIENTS (3)

CITRIC ACID MONOHYDRATEInactive
Quantity: 10 mg in 1 mL
Code: 2968PHW8QP
Classification: IACT
DACARBAZINEActive
Quantity: 10 mg in 1 mL
Code: 7GR28W0FJI
Classification: ACTIB
MANNITOLInactive
Quantity: 3.75 mg in 1 mL
Code: 3OWL53L36A
Classification: IACT

DACARBAZINE

PRODUCT DETAILS

NDC Product Code63323-127
Application NumberANDA075371
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateOctober 20, 2022
Generic NameDACARBAZINE

INGREDIENTS (3)

CITRIC ACID MONOHYDRATEInactive
Quantity: 10 mg in 1 mL
Code: 2968PHW8QP
Classification: IACT
MANNITOLInactive
Quantity: 5 mg in 1 mL
Code: 3OWL53L36A
Classification: IACT
DACARBAZINEActive
Quantity: 10 mg in 1 mL
Code: 7GR28W0FJI
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dacarbazine - FDA Drug Approval Details